{"id":"NCT00721123","sponsor":"Hoffmann-La Roche","briefTitle":"A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis","officialTitle":"Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2008-07-23","resultsPosted":"2013-10-21","lastUpdate":"2013-11-28"},"enrollment":538,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra","Actemra","Tocilizumab (MRA)","TCZ"]}],"arms":[{"label":"Tocilizumab 8 mg/kg","type":"EXPERIMENTAL"}],"summary":"This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.","primaryOutcome":{"measure":"Adverse Event (AE) Summary Over Time","timeFrame":"through 264 Weeks","effectByArm":[{"arm":"Months 0 - 12","deltaMin":433,"sd":null},{"arm":"Months 13 - 24","deltaMin":390,"sd":null},{"arm":"Months 25 - 36","deltaMin":333,"sd":null},{"arm":"Months 37 - 48","deltaMin":294,"sd":null},{"arm":"Months Greater Than 48","deltaMin":329,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":69,"countries":["Argentina","Australia","Austria","Brazil","Bulgaria","Canada","France","Germany","Hong Kong","Hungary","Israel","Italy","Mexico","Singapore","Slovakia","Switzerland","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":199,"n":538},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Hypertension","Urinary tract infection","Headache"]}}